Read More

Bristol Myers’ Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion

On Monday, the FDA approved Bristol Myers Squibb Co's (NYSE: BMY) Reblozyl (luspatercept-aamt) for anemia without previous erythropoiesis-stimulating agent use (ESA-naïve) in adult patients with very low-to-intermediate-risk myelodysplastic syndromes (MDS) who may require regular 

BMY